Pharmafile Logo

What oncologists really want from booth strategy

August 19, 2025 | Congress, Inizio, oncology 

- PMLiVE

Simon Davenport, Global Head of Environments, Emota, an Inizio Engage company 

At this year’s ASCO® congress, the spotlight wasn’t just on science – it was on how the industry engages. Supporting over 30 clients and delivering 185 projects, Inizio witnessed the shift toward smarter, more sustainable congress environments.

Key takeaways included:

  • Oncologists want interactive learning: Engagement is moving beyond slides, with responsive booths, interactive LED walls, and digital-first experiences extending conversations well past the industry’s six-minute average.

  • Smart spaces are here to stay: With heat mapping, AI-powered personalization, and real-time content optimization, booths are evolving into dynamic, intelligent environments that adapt to audience needs.

  • Sustainability as strategy: Inizio’s circularity-first booth design delivered a 70% CO₂e reduction, 70.7% recyclability, and major cost savings – results that earned industry-leading awards and set a benchmark for measurable impact.

In a crowded oncology market, strategy-led storytelling, analytics-driven design, and sustainability-centered innovation are becoming essential to cut through the noise. The future of congress engagement will be intentional, data-informed, and deeply aligned with healthcare professionals’ learning preferences.

Read Simon’s full article here, or explore more in Inizio’s on-demand webinar Beyond the booth: Big ideas, smart spaces & strategic insights from ASCO® 2025.

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

Infographic: Conference Live

Conference Live gives you real-time insights, utilising the multimedia functionality of the smartphone in an innovative mobile app methodology. We conduct mobile conference research amongst physicians attending conferences, giving our clients...

Blog: The Cost of Counterfeits

The sale of counterfeit drugs is growing at twice the rate of legitimate pharmaceuticals and pharma companies stand to lose more than just profits from the fallout of counterfeit identification.

Video: Self-pay and Emerging Markets

A key feature of emerging markets is that patients often have to pay for a high proportion of their healthcare costs themselves. For all but the most severe conditions, public...

News: Therapy Watch HCV expands into 4 additional EU markets

The HCV market has been growing and changing remarkably quickly and with the development of new and improving drugs, the treatment of HCV has moved on in a short space...

News: Research Partnership launches new patient report – Living with Ulcerative Colitis

Living with UC is a quantitative study conducted online amongst 325 patients, including both adult and paediatric patients diagnosed with ulcerative colitis in 5 EU markets (France, Germany, Italy, Spain...

Summer Intern experience at Research Partnership

We look for bright and inquisitive people who want to learn in a company that's pushing the boundaries of pharmaceutical market research

Double win at Communiqué 2016: Pegasus scoops awards for Consultancy of the Year (for the second time!) and Excellence in Media Relations

Pegasus, an Ashfield company, part of UDG Healthcare plc, is delighted to have won the prestigious Consultancy of the Year award at the 2016 Communiqué Awards in London. The judges...

Beyond Andrology: Trends in Men’s Health in Emerging Markets

Published in eyeforpharma July 2016 by Rachel Howard

Pharma & life sciences division growth allows Pegasus to fill three new senior positions

Pegasus has expanded its pharma & life sciences senior team by appointing a new Associate Director and promoting two members of the existing team to Account Directors.

Infographic: HIV Market Snapshot

Our latest HIV infographic, taken from data collected from syndicated tracking study Therapy Watch, reveals that more than 3 in 5 naive or switch patients are currently treated with a STR (single...